CXCL8 and neoplasm: Taken together the above data would suggest that treatment with AZD5069 could, at least in part, counteract the CXCL8-induced tumor cell trafficiking not only by selectively blocking the migratory CXCR2 receptor but, at least in some of the here tested thyroid cancer cell types also by down-regulating it.